Haemodynamic changes and side-effects of induction of anaesthesia with etomidate were evaluated in 60 ASA Class I or Il patients. The objective was to find an optimal pre-induction dose of fentanyl which eliminated haemodynamic changes and side-effects during induction and intubation without introducing other problems. Patients were randomly assigned to four groups according to the pretreatment dose of fentanyl (Group I = 2 ml normal saline; Group Il = 1 00 ~g of fentanyl; Group III = 250~g of fentanyl; Group IV = 500 ~g of fentanyl) administered intravenously five minutes prior to induction of anaesthesia with etomidate, 0.3 mg/kg. There was an increasing incidence of apnoea (53, 87, 87 and 100% in Groups I-IV respectively) and a decreasing incidence of myoclonus (60, 33, 13 and 0% in Groups I-IV respectively) and injection pain (53, 13, 7 and 0% in Groups I-IV respectively), P< 0.002 chi-square test for linear trends, with increasing fentanyl dosage. The incidences of postoperative nausea and vomiting were similar in the four groups. There were also significant linear regression relationships (P< 0.01 ANOVA for linear regression) between increasing doses of fentanyl administered before etomidate and the prevention of increases in systolic blood pressure and heart rate during the induction-intubation sequence. The data demonstrate that increasing pre-induction doses of fentanyl are more effective at minimising side-effects and preventing increases in systolic arterial blood pressure and heart rate but also increase the incidence of apnoea during induction. The results suggest that 500 ~g of fentanyl is an ideal pretreatment dose in fit patients prior to anaesthetic induction with etomidate.
properties etomidate has not gained widespread clinical acceptance in the United States.1,2 The reason for this is not entirely clear but may be partly related to inhibition of adrenal synthesis of cortisone and several annoying side-effects. 3, 4 Most prominent among these are pain on injection, myoclonus, and postoperative nausea and vomiting. 4 ,7 In addition, etomidate does not have analgesic properties and laryngoscopy and tracheal intubation usually result in impressive increases in heart rate and arterial blood pressure. 5 Pretreatment with narcotic analgesics (usually fentanyl) can decrease the incidence of pain on injection and myoclonus during induction of anaesthesia with etomidate and blunt the haemodynamic response to tracheal intubation. 6 ,7 The object of this study was to determine whether there is an optimal dose of fentanyl which eliminates haemodynamic changes and side effects during induction and intubation without introducing other problems. METHODS The study was approved by the University of Utah Health and Sciences Institutional Review Board. Sixty ASA Class I or 11 patients, aged 18-70 years, undergoing elective general, orthopaedic, or gynaecologic surgical procedures expected to last one hour or longer served as the experimental subjects. All patients gave their written informed consent at the preoperative visit.
Following enrolment in the study, the patients were randomly assigned to one of four groups of 15 patients each and had preoperative heart rates and arterial blood pressures measured via palpation and a standard blood pressure cuff, respectively. Patients in Group I received normal saline (2 ml) while those in Groups 11, III and IV were given 100, 250 or 500)lg of fentanyl respectively 5 minutes prior to induction of anaesthesia with etomidate.
All patients were premedicated with diazepam (0.1 mglkg) orally one hour prior to the scheduled time of operation. Upon arrival in the operating room, an intravenous infusion was started with either an 18 or 20 gauge catheter in the most readily available forearm or hand vein. An automated blood pressure cuff was applied to an upper arm, and a bipolar lead 11 electrocardiogram was displayed continuously with an electronic rate read-out. After a 5-minute stabilisation period, baseline systolic arterial blood pressure (SBP) and respiratory and heart rates (RR, HR) were recorded. All patients then received pancuronium (1 mg, IV) and after one minute measurements were repeated. The pretreatment dose of fentanyl (2 ml of saline in Group I) was then administered and all variables remeasured three minutes later by an investigator who was blinded to the pretreatment medication. Patients were then given etomidate (0.3 mg/kg, IV) as a bolus over 15-30 seconds in the rapid running IV, and measurements repeated after two minutes. Following this, succinylcholine (1.5 mg/kg, IV) was administered, variables re measured in one minute, the trachea intubated under direct vision and haemodynamics remeasured one minute later. The maintenance anaesthetics, isoflurane and nitrous oxide, were then started.
During induction of anaesthesia pain on injection was noted if volunteered by the patient or was solicited by the investigator if the patient grimaced. Patients were considered apnoeic if they did not spontaneously initiate ventilation over a period of 30 seconds at any time after they received fentanyl or saline until they were given succinylcholine. Myoclonus was defined as any abnormal muscle movement not associated with the use of succinylcholine and rigidity as difficulty with positive pressure ventilation not correctable with the insertion of an oral airway. The patients were continuously observed in the recovery room and interviewed at the end of their recovery room stay and 24-48 hours after operation to determine whether they experienced any nausea or vomited.
Demographics and preoperative and baseline vital signs were compared among the four groups by one-way analysis of variance (ANOV A); individual comparisons were done with Bonferroni adjusted t-tests. Frequency counts of gender ratios and side effects among the four groups were analysed with a chisquare test for linear trends. One-way ANOVA for linear regression was used to compare the effects of increasing fentanyl doses on vital signs during anaesthetic induction. To summarise the overall stability of HR and SBP, the maximum HR and maximum SBP for each patient during anaesthetic induction and endotracheal intubation were noted. To adjust for differences in baseline vital signs, the logarithm ofthe ratio of each variable divided by the baseline value was used for analysis. Statistical software from the BMDP statistical library was used, in particular the P1D, P3D, Group I saline; Group II = fentanyl, 100 )lg; Group III = fentanyl, 250 )lg; Group IV fentanyl, 500 )lg.
P7D, P4F, and P4V modules. 8 Alpha was set at 0.05 for statistical significance. RESULTS There were no significant differences between the groups with respect to age (mean 51, SD 8; range 18-70 years), weight (mean 68, SD 4; range 59-75 kg), anaesthesia time (mean 91, SD 12; range 61-153 min), preoperative HR, SBP and RR; baseline SBP, RR, and duration of recovery room stay. Preoperative and baseline HR and arterial blood pressures were similar in all groups. Baseline HR ( Table  1 ) was significantly lower in Group I than in Group III and Group IV (P< 0.01). Random allocation of the patients to the four groups resulted in the chance distribution of more males to Group I (11 of 14) and more females to Group IV (12 of 15). Groups 11 and III were more evenly distributed with male/female ratios of 7:8 and 6:9 respectively.
No patient in any group became unresponsive, rigid, or apnoeic after the administration of saline or fentanyl and none received or required naloxone at the conclusion of surgery. The incidence of myoclonus, apnoea, and injection pain after the administration of etomidate is shown in Table 2 . There is a statistically significant linear trend for each of these side-effects. The linear trend reveals that with increasing *p= 0.0002; tP> = 0.001; tP= 0.0017, chi-square test for linear trends. Group I = saline; Group II = fentanyl 100 )lg; Group III = fentanyl 250 )lg; Group IV fentanyl 500 )lg. fentanyl dosage, there was an increasing incidence of apnoea (X~= 9.82; p= 0.0017) and a decreasing incidence of myoclonus (X~= 15.341; P= 0.001) and injection pain (X~= 13.92; P= 0.0002). There were no statistically significant differences between the groups with regard to the incidence of nausea or vomiting in the recovery room or postoperative period. There was almost a linear trend for increasing postoperative nausea (chi-square for linear trend = 3.413, P = 0.0647) with increasing dose offentanyl. Tables 1 and 3 display HR and SBP during the induction-intubation sequence. From two minutes after etomidate, until one minute after intubation, there was a linear relationship between drug dose and HR and SBP (as a percent of the baseline value) at each measurement. The overall stability of HR and SBP during the study is best summarised by the maximum columns of Tables 1 and 3 . There were significant linear regression relationships (X2 = 8.42 and X2 = 8 91
ANOV A for linear regression)
between the dose of fentanyl administered before etomidate and the prevention of increases in SBP and HR during the induction-intubation sequence.
DISCUSSION
While previous studies have demonstrated that myoclonus, pain on injection and increases in arterial blood pressure and heart rate during laryngoscopy and endotracheal intubation can be attenuated following pretreatment with fentanyl,s.7 none has assessed whether these problems can be eliminated with higher doses of the opioid and, if so, at what physiologic (pharmacologic) cost. The results of this investigation demonstrate that increasing preinduction doses of fentanyl are more effective at minimizing the above side-effects and sufficient doses can totally eliminate them. Unfortunately, higher pre-treatment doses of fentanyl also cause a high incidence of apnoea (after etomidate and before paralysis) and probably more postopertative nausea.
Pretreatment with fentanyl did not result in chest wall rigidity in any patient in this study. We believe that this low incidence is at least partly related to the use of a small dose of pancuronium (1.0 mg, IV) prior to administration of fentanyl. While these findings indicate that the incidence of rigidity is low when 500 ~g of fentanyl is given before etomidate, it probably is not absent, as others have described rigidity after as little as 100-150 ~g of fentanyp,lO Similarly, that no patient required a narcotic antagonist either immediately after operation or in the recovery room, even though many of the operations lasted only slightly more than an hour, should not be construed to mean that respiratory depression sufficient to require mechanical re~piratory support or a narcotic antagonist mIght not be an occasional occurrence. This study did not evaluate the proposed advantages of etomidate in patients with limited cardiovascular reserve and therefore may not be directly applicable to that group. Indeed, the small though insignificant decreases in HR and SBP in Group IV after etomidate and succinylcholine in these ASA Class I and 11 patients suggest that the optimal fentanyl pretreatment dose in ASA Class III and IV patients might be somewhat less. A recent study from our institution has demonstrated that 250 f.lg of fentanyl before etomidate eliminated all increases in heart rate and arterial blood pressure produced by the induction-intubation sequence (without resulting in hypotension and a reduction in cardiac output) in patients with significant cardiovascular disease (NYHA Class III and IV).7 These findings, when combined with our results in this study, suggest that the optimal pretreatment dose of fentanyl (a dose which ablates increases in HR and SBP during the induction-intubation sequence without causing significant decreases in these variables just prior to intubation) is approximately 500 f.lg in fit patients but less 250 f.lg, in less fit patients with significant cardiovascular disease.
A legitimate criticism of this study is that the four groups did not have similar sex distributions. Indeed, only four of the 15 patients in Group I were female as compared to 12 of the 15 in Group IV. Since Group IV had the highest incidence of apnoea, the lowest of pain on injection and myoClonus and the most stable haemodynamics during the induction-intubation sequence, a possible hypothesis is that these differences were related to the high percentage of females in that group. We do not believe that this explanation is valid as previous studies by ourselves and others have indicated that if there is a sex difference, females tend to h~ve somewhat higher rather than lower incidences of myoclonus, pain on injection and postoperative nausea and vomiting after etomidate than males. 5, II While it is possible that the gender difference between Group I and the other three groups could have been a Anaesthesia and Intensive Care. Vol. 16, No. 2, May, 1988 cause of the difference in baseline heart rate among the groups, we doubt that it influenced the haemodynamic differences measured during the anaesthetic induction-intubation sequence because the data were analysed by percent changes from baseline. Since each ~ubject served as his or her own control, the mfluence of gender on change of heart rate and blood pressure versus time should have been neutralised.
In conclusion, our findings indicate that the effectiveness of fentanyl in reducing and/or eliminating the induction side-effects of etomidate and blunting the haemodynamic changes associated with the inductionintubation sequence is dose-dependent. The data suggest that 500 f.lg of fentanyl eliminates myoclonus, pain on injection, and increases in HR and SBP during the induction-intubation sequence in ASA Class I and 11 patients but produce a high incidence of apnoea (100%) during induction and nausea (67%) and vomiting (47%) postoperatively.
